← Eichor
Study identifier: NCT05761899 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Safety and Efficacy of PMT Therapy of hPAP

Condition: Hereditary Pulmonary Alveolar Proteinosis  ·  Sponsor: Children's Hospital Medical Center, Cincinnati

PhasePhase 1/Phase 2
Planned participants3
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

The major goal of this study is to evaluate a new type of cell transplantation therapy for individuals with hereditary PAP, study a new treatment that may be useful for treatment of other diseases, and research mechanisms that drive the development and function of lung macrophages.

This description comes directly from the study's public registry record.

Talk to the study team

Bruce Trapnell  ·  513-636-6361  ·  Bruce.Trapnell@cchmc.org

Brenna Carey  ·  513-636-8916  ·  Brenna.Carey@cchmc.org

Always discuss trial participation with your own doctor first.

Locations (1)

Cincinnati Children's Hospital Medical CenterCincinnati, Ohio, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05761899